CJC-1295/Ipamorelin protocol: dosing, timing, and what the research shows

CJC-1295 (without DAC) is a GHRH analogue — it binds pituitary GHRH receptors and amplifies the signal for growth hormone release. Ipamorelin is a GHRP (growth hormone releasing peptide) — a selective GH secretagogue that amplifies the amplitude of existing GH pulses without elevating cortisol or prolactin (unlike GHRP-2 and GHRP-6). The combination produces synergistic GH output: GHRH acts on signal amplitude, GHRP acts on pulse frequency. The net effect is a meaningful increase in pituitary GH secretion that remains physiologic and pulsatile.

The synergy operates at the pituitary level: GHRH receptor occupancy upregulates GHRP receptor expression. Clinical data (Sigalos & Pastuszak, 2018) shows approximately 18% IGF-1 increase with the combination at 12 weeks, compared to approximately 9% with either peptide alone. The combination also produces a more physiologic pulsatile GH release pattern than exogenous synthetic HGH, which delivers a large non-pulsatile bolus. Pulsatile release is important for maintaining pituitary sensitivity over the course of a cycle.

CJC-1295 without DAC: 100–200mcg per injection. Ipamorelin: 100–200mcg per injection. Both peptides are drawn into the same syringe and administered as a single subcutaneous injection. Frequency: 5 days on, 2 days off — this prevents receptor desensitization that occurs with daily continuous use. Duration: 3–6 months per cycle, followed by a 4–8 week break. Starting at the lower end of the dose range (100mcg each) and titrating up based on IGF-1 response at 8 weeks is the standard physician approach.

The largest natural GH pulse occurs 60–90 minutes after sleep onset. Injecting CJC-1295/Ipamorelin 30–45 minutes before sleep onset aligns the secretagogue's action window with this natural peak — amplifying rather than replacing the physiologic pulse. The critical constraint: insulin completely blocks GH secretagogue action. No carbohydrates for at least 2 hours before injection. No food for 90 minutes after. A high-carbohydrate meal 1 hour before injection can reduce efficacy by 60–80% through insulin-mediated suppression of GH release.

Weeks 2–4: subjective improvements in sleep quality and sleep depth — often the first reported effect. Weeks 4–8: faster exercise recovery, reduced delayed onset muscle soreness, mild increase in lean mass retention. Weeks 8–12: measurable IGF-1 rise on serum testing (fasting, morning draw). Weeks 12–24: body composition changes become visible — modest lean mass increase, fat redistribution. Some patients report improved skin quality and cognitive clarity in this phase. Individual variation is significant; IGF-1 testing at 8 weeks confirms whether the protocol is producing the expected biological response.

IGF-1 is the primary monitoring biomarker. Draw fasting in the morning (GH and IGF-1 have diurnal variation). Test at baseline, 8 weeks into the cycle, and at 6 months. Target range: 200–350 ng/mL for adults, age-adjusted. If IGF-1 rises above 400 ng/mL: reduce the dose. Fasting glucose should be checked at baseline and 12 weeks — GH has counter-regulatory anti-insulin effects and can slightly impair glucose tolerance at higher doses. Random spot-check growth hormone testing is not clinically useful; IGF-1 is the correct monitoring biomarker.

Water retention in weeks 1–3: transient, resolves without intervention. Mild tingling or numbness — carpal tunnel-like — at higher doses: reduce to the lower dose range. Vivid or unusual dreams: expected and not concerning — a positive sleep-depth signal. Headache: usually hydration-related; ensure adequate water intake. Lethargy the morning after injection: shift injection timing to 60 minutes before sleep rather than immediately before. No cardiovascular side effects have been documented at clinical therapeutic doses in trial data.

The physician assessment considers: baseline IGF-1 (if already above 300 ng/mL in a young patient, the additive effect will be smaller), symptoms consistent with sub-optimal GH secretion (fatigue, poor recovery, body composition plateau despite training), concurrent TRT status (testosterone and GH have synergistic effects on body composition). Age above 35 is the most common patient profile, as natural GH secretion declines approximately 15% per decade from peak. GLP-1 patients frequently combine this protocol for body recomposition support — offsetting lean mass loss during caloric restriction.

Active malignancy: GH can accelerate tumor growth via IGF-1 upregulation — confirmed cancer is an absolute contraindication. Untreated acromegaly or confirmed elevated IGF-1 at baseline. Pregnancy or breastfeeding. Active diabetic retinopathy. Uncontrolled diabetes (HbA1c above 9.0%) — GH's counter-regulatory insulin effect is clinically significant at this level of glycemic dysfunction. These are physician-assessed; none are patient self-determined.

Physician consultation, IGF-1 baseline and monitoring, PCAB-accredited compounding pharmacy. Everything in one protocol.

Frequently Asked Questions